VBL's VB-111 preclinical data against metastatic cancer to be presented at AACR meeting

Apr 1 2011

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced two upcoming presentations of preclinical data from the company's VB-111 program at the American Association for Cancer Research (AACR) 102^nd Annual Meeting. Eyal Breitbart, Ph.D., vice president of research at VBL Therapeutics, is scheduled to present a poster entitled "VB-111 a Novel Anti-angiogenic Vector and a Promising Treatment for Metastatic Cancer in Combination with Other Anticancer Drugs" on Tuesday, April 5, 2011 at 8:00 a.m. EDT in Orlando, FL. Andrew J. Brenner, M.D., Ph.D., Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio, TX, is scheduled to present a poster entitled "Antiangiogenic gene therapy with VB-111 is Active in Glioblastoma Xenografts" on Wednesday, April 6, 2011 at 8:00 a.m. EDT.

VB-111 is a dual-action, anti-angiogenic and Vascular Disruptive Agent (VDA) that utilizes VTS^™, VBL's proprietary platform technology for cancer therapy. VB-111 is an intravenously administered VDA that works in a manner akin to a "biological knife" to destroy tumor vasculature, cutting off the blood vessels feeding the tumor. Preclinical pharmacological and toxicology studies of VB-111 showed specificity for the tumor tissue, no significant damage to non-cancerous tissues or to the normal vasculatures in the body, and a more than 90 percent reduction in metastatic lung cancer model with one injection, with similar efficacy in other tumor models. A Phase 1 "all-comers" study of VB-111 in 33 patients with advanced metastatic cancer demonstrated antitumor activity and no effects on liver function or major changes in complete blood count. VB-111 is currently in Phase 2 clinical trials for thyroid cancer and glioblastoma.